Keywords: Targacept, TC-5619, ADHA, Ph II, Study failure, Job cuts

Targacept ADHD candidate fails to meet primary endpoints in Ph II study

Article | 18 September 2012

Print This

In a second disappointment this year, US drug developer Targacept (Nasdaq: TRGT) said yesterday that top-line results from a Phase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in